Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (NYSE: RMD) drives innovation in digital health and respiratory care through cloud-connected medical devices and remote patient management platforms. This news hub provides investors and healthcare professionals with timely updates on the company's market activities and clinical advancements.
Access curated press releases, earnings reports, and regulatory filings alongside analysis of product launches and partnership announcements. Our repository tracks developments across ResMed's core focus areas: sleep apnea solutions, COPD management technologies, and out-of-hospital care software platforms.
Stay informed about FDA clearances, clinical trial results, and global market expansions through verified sources. The page serves as a comprehensive resource for monitoring ResMed's progress in merging medical device engineering with data-driven healthcare solutions.
Bookmark this page for streamlined access to strategic updates impacting respiratory care innovation and digital health investment opportunities. Check regularly for new developments in ResMed's mission to transform chronic disease management worldwide.
ResMed (NYSE: RMD) announced its plans to release third-quarter financial results for fiscal year 2023 on April 27, after market close. The company will host a webcast at 1:30 p.m. PDT to discuss the results and share additional forward-looking information. The event demonstrates ResMed's commitment to transparency with investors and stakeholders. Following the live webcast, a replay will be available on the company’s website, providing convenient access to the information shared. ResMed, known for its innovative digital health technologies and cloud-connected medical devices, serves over 140 countries, aiming to enhance healthcare delivery for chronic conditions.
ResMed (NYSE: RMD) announced that David Pendarvis, its chief administrative officer and global general counsel, will retire on June 30, 2023, after over 20 years with the company. He will transition to a consulting role until December 31, 2023. ResMed plans to conduct an internal search for his successor, aiming for a seamless transition. Amy Wakeham, currently Vice President of Corporate Communications & Investor Relations, has been appointed as the new Chief Communications and Investor Relations Officer, effective April 1, 2023. CEO Mick Farrell praised Pendarvis for his leadership during ResMed's transformation into a $30 billion global leader in digital health.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
